New Data Reveals Market Potential For Rare Cannabinoids Like THCV and CBC
Move over, THC and CBD—there’s a new generation of cannabinoids stepping into the spotlight, and the data says they’re here to change the game.
A new 2024 market report from BayMedica, a leading rare cannabinoid manufacturer and research partner to top wellness brands, reveals that lesser-known compounds like THCV and CBC aren’t just scientific curiosities—they’re market movers with untapped commercial potential.
Analyzing retail performance across 13 U.S. states, BayMedica found that THCV-infused products yield an average 23.7% higher margin than other SKUs, making it one of the most promising cannabinoid ingredients in today’s cannabis and nutraceutical markets. Known for its energizing effects and potential appetite-suppressing properties, THCV has already sparked curiosity among both medical professionals and adventurous consumers.
Gummies Take the Lead
When it comes to delivery, gummies are dominating. The report shows that rare cannabinoid formulations in gummy form are outperforming other product types thanks to their dose control, consumer compliance, and ability to mask bitterness—a major win for compounds that can otherwise be challenging to formulate.
CBC: The Sleeping Giant
While THCV is enjoying the early buzz, CBC (cannabichromene) remains an underdog—despite strong scientific evidence of its potential. CBC interacts with key receptors like TRPV1 and TRPA1 and can influence levels of anandamide (AEA), often referred to as the “bliss molecule.” The catch? Current products tend to underdose CBC, leaving much of its potential untapped.
Even more surprising: There are no standardized formulation guidelines for stacking CBC and THCV, creating a wide-open field for innovation in dose architecture, delivery formats, and cross-category applications—from pharmaceutical drugs to functional wellness products.
An Industry on the Verge
According to BayMedica, this gap between science and market execution represents one of the biggest growth opportunities in cannabis today. The company is making its full dataset available to select reporters and offering expert insights from leaders like Dr. Shane Johnson, MD (medical and regulatory), Dr. Tony Ferrari, PhD (formulation and cannabinoid pharmacology), and Jerry Griffin (minor cannabinoid market trends).
For cannabis brands, formulators, and investors, the message is clear: rare cannabinoids aren’t just the next frontier—they may be the key to the industry’s long-term growth.
